Renexxion

Executive Summary

Renexxion Ireland Limited is a private biopharmaceutical company developing naronapride, a novel pan-GI prokinetic agent for gastrointestinal disorders. Currently in Phase 2, naronapride targets conditions such as gastroparesis and chronic idiopathic constipation, offering a differentiated mechanism as a serotonin 5-HT4 receptor agonist. The company operates as a wholly owned subsidiary of Renexxion, Inc., based in Dublin, Ireland, with strategic partnerships to advance clinical programs. With a focused pipeline and an unmet need in GI motility disorders, Renexxion is positioned to address a significant market opportunity, though it remains in early clinical stages without approved products or disclosed financing. The execution of upcoming milestones will be critical for value creation.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data for naronapride in gastroparesis50% success
• Q2 2026Licensing or partnership deal for naronapride outside US40% success
• Q3 2026Regulatory clarity on Phase 3 trial design from FDA70% success